Patents by Inventor Ulrich Brinkmann

Ulrich Brinkmann has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • BISPECIFIC ANTI-VEGF/ANTI-ANG-2 ANTIBODIES
    Publication number: 20170369566
    Abstract: The present invention relates to bispecific antibodies against human VEGF and against human ANG-2, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Application
    Filed: May 23, 2017
    Publication date: December 28, 2017
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Monika Baehner, Ulrich Brinkmann, Guy Georges, Remko Albert Griep, Sabine Imhof-Jung, Anita Kavlie, Hubert Kettenberger, Christian Klein, Joerg Thomas Regula, Wolfgang Schaefer, Juergen Michael Schanzer, Werner Scheuer, Stefan Seeber, Markus Thomas
  • Anti-biotin antibodies and methods of use
    Patent number: 9765153
    Abstract: The invention provides anti-biotin antibodies and methods of using the same.
    Type: Grant
    Filed: December 19, 2014
    Date of Patent: September 19, 2017
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Ulrich Brinkmann, Guy Georges, Michael Grote, Eike Hoffmann
  • Bispecific anti-VEGF/anti-ANG-2 antibodies
    Patent number: 9708396
    Abstract: The present invention relates to bispecific antibodies against human VEGF and against human ANG-2, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Grant
    Filed: February 27, 2014
    Date of Patent: July 18, 2017
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Monika Baehner, Ulrich Brinkmann, Guy Georges, Remko Albert Griep, Sabine Imhof-Jung, Anita Kavlie, Hubert Kettenberger, Christian Klein, Joerg Thomas Regula, Wolfgang Schaefer, Juergen Michael Schanzer, Werner Scheuer, Stefan Seeber, Markus Thomas
  • ANTI-BRDU ANTIBODIES AND METHODS OF USE
    Publication number: 20170114150
    Abstract: The invention provides anti-BRDU antibodies and methods of using the same.
    Type: Application
    Filed: December 16, 2016
    Publication date: April 27, 2017
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Ulrich BRINKMANN, Guy GEORGES, Johannes AUER, Wilma LAU
  • COVALENTLY LINKED HELICAR-ANTI-HELICAR ANTIBODY CONJUGATES AND USES THEREOF
    Publication number: 20170058050
    Abstract: Herein is reported a conjugate comprising a helicar motif amino acid sequence containing compound and an antibody that specifically binds to the helicar motif amino acid sequence characterized by a covalent bond between the helicar motif amino acid sequence containing compound and an amino acid residue in the CDR2 of the anti-helicar antibody, whereby the CDR2 is determined according to Kabat.
    Type: Application
    Filed: July 1, 2016
    Publication date: March 2, 2017
    Applicant: Hoffmann-La Roche Inc.
    Inventors: ULRICH BRINKMANN, GUY GEORGES, EIKE HOFFMANN, GEORG TIEFENTHALER, EKKEHARD MOESSNER, STEFAN DENGL, ACHIM GAERTNER
  • COVALENTLY LINKED POLYPEPTIDE TOXIN-ANTIBODY CONJUGATES
    Publication number: 20170058051
    Abstract: Herein is reported a conjugate of a haptenylated polypeptide toxin and an anti-hapten antibody, wherein a disulfide bond is formed between a cysteine residue either before or after the lysine residue that is used for hapten-conjugation and a cysteine residue in the CDR2 of the antibody, whereby the CDR2 is determined according to Kabat.
    Type: Application
    Filed: July 1, 2016
    Publication date: March 2, 2017
    Applicant: Hoffmann-La Roche Inc.
    Inventors: ULRICH BRINKMANN, EIKE HOFFMANN, STEFAN DENGL, KLAUS MAYER
  • MODIFIED PSEUDOMONAS EXOTOXIN A
    Publication number: 20170051072
    Abstract: The invention provides a Pseudomonas exotoxin A (PE) comprising an amino acid sequence having a substitution of one or more B-cell and/or T-cell epitopes. The invention further provides related chimeric molecules, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions. Methods of treating or preventing cancer in a mammal, methods of inhibiting the growth of a target cell, methods of producing the PE, and methods of producing the chimeric molecule are further provided by the invention.
    Type: Application
    Filed: June 23, 2016
    Publication date: February 23, 2017
    Inventors: Ira H. Pastan, Ronit Mazor, Masanori Onda, Byungkook Lee, Gerhard Niederfellner, Sabine Imhof-Jung, Ulrich Brinkmann, Werner Scheuer, Guy Georges
  • Complex of bi-specific antibody and digoxigenin conjugated to a therapeutic or diagnostic agent
    Patent number: 9574016
    Abstract: The present invention relates to complexes of a) bi-specific antibodies and antibody fragments against a target protein and b) a digoxigenin conjugated to a therapeutic or diagnostic agent, methods for their production, their use as a delivery platform for therapeutic or diagnostic agents, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Grant
    Filed: November 12, 2014
    Date of Patent: February 21, 2017
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Ulrich Brinkmann, Rebecca Croasdale, Wilma Lau, Guy Georges, Alexander Haas, Eike Hoffmann, Silke Metz, Olaf Mundigl, Werner Scheuer, Jan Olaf Stracke
  • ANTIBODIES AGAINST HUMAN ANGIOPOIETIN 2
    Publication number: 20170029493
    Abstract: The present invention relates to antibodies against human Angiopoietin 2 (anti-ANG-2 antibodies), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Application
    Filed: April 12, 2016
    Publication date: February 2, 2017
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Ulrich Brinkmann, Remko Albert Griep, Klaus Kaluza, Anita Kavlie, Christian Klein, Joerg Thomas Regula, Werner Scheuer
  • BIOSPECIFIC ANTI-HAPTEN/ANTI-BLOOD BRAIN BARRIER RECEPTOR ANTIBODIES, COMPLEXES THEREOF AND THEIR USE AS BLOOD BRAIN BARRIER SHUTTLES
    Publication number: 20160324984
    Abstract: Herein is reported a bispecific antibody comprising a first binding specificity that specifically binds to a haptenylated payload and a second binding specificity that specifically binds to a blood brain barrier receptor.
    Type: Application
    Filed: December 29, 2014
    Publication date: November 10, 2016
    Inventors: Ulrich Brinkmann, Guy Georges, Olaf Mundigl, Jens Niewoehner
  • Modified exotoxin A
    Patent number: 9388222
    Abstract: The invention provides a Pseudomonas exotoxin A (PE) comprising an amino acid sequence having a substitution of one or more B-cell and/or T-cell epitopes. The invention further provides related chimeric molecules, as well as related nucleic acids, recombinant expression vectors, host cells, populations of cells, and pharmaceutical compositions. Methods of treating or preventing cancer in a mammal, methods of inhibiting the growth of a target cell, methods of producing the PE, and methods of producing the chimeric molecule are further provided by the invention.
    Type: Grant
    Filed: October 3, 2014
    Date of Patent: July 12, 2016
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, Hoffman-La Roche Inc.
    Inventors: Ira H. Pastan, Ronit Mazor, Masanori Onda, Byungkook Lee, Gerhard Niederfellner, Sabine Imhof-Jung, Ulrich Brinkmann, Guy Georges
  • Multispecific antibodies comprising full length antibodies and single chain fab fragments
    Patent number: 9382323
    Abstract: The present invention relates to multispecific, especially bispecific antibodies comprising full length antibodies and single chain Fab fragments, methods for their production, pharmaceutical compositions containing the antibodies, and uses thereof.
    Type: Grant
    Filed: March 31, 2010
    Date of Patent: July 5, 2016
    Assignee: Roche Glycart AG
    Inventors: Ulrich Brinkmann, Peter Bruenker, Rebecca Croasdale, Christian Klein, Erhard Kopetzki, Ekkehard Moessner, Joerg Thomas Regula, Juergen Michael Schanzer, Jan Olaf Stracke, Pablo Umana
  • Antibodies against human angiopoietin 2
    Patent number: 9340609
    Abstract: The present invention relates to a method of treating a disease or disorder in a patient comprising administering, to a patient in need of such treatment, an antibody which binds specifically to human angiopoietin-2 (ANG-2), wherein said antibody comprises: (A) a heavy chain variable domain which comprises a CDR3 region of SEQ ID NO: 1, a CDR2 region of SEQ ID NO: 2 and a CDR1 region of SEQ ID NO: 3; (B) a light chain variable domain which comprises a CDR3 region of SEQ ID NO: 4, a CDR2 region of SEQ ID NO: 5 and a CDR1 region of SEQ ID NO: 6.
    Type: Grant
    Filed: December 4, 2012
    Date of Patent: May 17, 2016
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Ulrich Brinkmann, Remko Albert Griep, Klaus Kaluza, Anita Kavlie, Christian Klein, Joerg Thomas Regula, Werner Scheuer
  • Cell-penetrating peptides and uses thereof
    Patent number: 9303076
    Abstract: The present invention relates to the identification and functional characterization of human cell-penetrating peptides (CPPs) and their use; in particular as transfection vehicles.
    Type: Grant
    Filed: May 7, 2015
    Date of Patent: April 5, 2016
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Ulrich Brinkmann, Alexander Haas, Daniela Maisel
  • Cell-penetrating peptides and uses thereof
    Patent number: 9303075
    Abstract: The present invention relates to the identification and functional characterization of human cell-penetrating peptides (CPPs) and their use; in particular as transfection vehicles.
    Type: Grant
    Filed: December 12, 2012
    Date of Patent: April 5, 2016
    Assignee: HOFFMANN-LA ROCHE INC.
    Inventors: Ulrich Brinkmann, Alexander Haas, Daniela Maisel
  • COMPLEX OF BI-SPECIFIC ANTIBODY AND DIGOXIGENIN CONJUGATED TO A THERAPEUTIC OR DIAGNOSTIC AGENT
    Publication number: 20160009823
    Abstract: The present invention relates to complexes of a) bi-specific antibodies and antibody fragments against a target protein and b) a digoxigenin conjugated to a therapeutic or diagnostic agent, methods for their production, their use as a delivery platform for therapeutic or diagnostic agents, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Application
    Filed: November 12, 2014
    Publication date: January 14, 2016
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: Ulrich Brinkmann, Rebecca Croasdale, Wilma Dormeyer, Guy Georges, Alexander Haas, Eike Hoffmann, Silke Metz, Olaf Mundigl, Werner Scheuer, Jan Olaf Stracke
  • ANTIBODIES AGAINST HUMAN ANGIOPOIETIN 2
    Publication number: 20150284457
    Abstract: The present invention relates to antibodies against human Angiopoietin 2 (anti-ANG-2 antibodies), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Application
    Filed: June 4, 2015
    Publication date: October 8, 2015
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: Ulrich Brinkmann, Remko Albert Griep, Klaus Kaluza, Anita Kavlie, Christian Klein, Joerg Thomas Regula, Werner Scheuer
  • COVALENTLY LINKED ANTIGEN-ANTIBODY CONJUGATES
    Publication number: 20150258209
    Abstract: Herein is reported a conjugate comprising an antigen and an antibody that specifically binds to the antigen wherein a covalent bond is formed between the antigen and an amino acid residue in the CDR2 of the antibody, an antibody comprising a cysteine residue at amino acid position 53 (according to Kabat) in the heavy chain CDR2 and uses thereof.
    Type: Application
    Filed: December 19, 2014
    Publication date: September 17, 2015
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: JOERG BENZ, ULRICH BRINKMANN, STEFAN DENGL, SEBASTIAN DZIADEK, GUY GEORGES, MICHAEL GROTE, ALEXANDER HAAS, EIKE HOFFMANN
  • CELL-PENETRATING PEPTIDES AND USES THEREOF
    Publication number: 20150239947
    Abstract: The present invention relates to the identification and functional characterization of human cell-penetrating peptides (CPPs) and their use; in particular as transfection vehicles.
    Type: Application
    Filed: May 7, 2015
    Publication date: August 27, 2015
    Applicant: HOFFMANN-LA ROCHE INC.
    Inventors: Ulrich BRINKMANN, Alexander HAAS, Daniela MAISEL
  • ANTI-THEOPHYLLINE ANTIBODIES AND METHODS OF USE
    Publication number: 20150238628
    Abstract: The invention provides anti-theophylline antibodies and methods of using the same.
    Type: Application
    Filed: December 18, 2014
    Publication date: August 27, 2015
    Applicant: Hoffmann-La Roche Inc.
    Inventors: ULRICH BRINKMANN, GUY GEORGES, EIKE HOFFMANN